摘要
目的观察替吉奥(S-1)联合顺铂治疗晚期胃癌临床疗效和毒副作用。方法选取自2008年5月至2010年12月来中山市人民医院就诊的且确诊为晚期胃癌35例患者的临床资料。35例患者均接受替吉奥联合顺铂治疗,顺铂75mg/m2,分3d滴注,替吉奥80mg/(m2d),每日分2次口服,连服14d后停药7d,每21d为1个周期,连用2周期进行影像学检查和实验室检查评价替吉奥联合顺铂治疗的疗效和不良反应。结果本组报告35例患者通过替吉奥联合顺铂治疗,完全缓解(CR)0例,部分缓解(PR)有18例、稳定(SD)有9例、进展(PD)有8例,总有效有18例,总有效率为51.4%,疾病控制27例,疾病控制率为77.1%。结论在治疗晚期胃癌中,替吉奥联合顺铂不良反应小,有效安全,近期疗效较好,远期疗效有待进一步观察。
Objective To observe the efficacy and toxicity of Cisplatin combined with Gimeraciland Oteracil Porassium capsules in the treatment of patients with advanced gastric carcinoma.Methods 35 previous patients with advanced gastric carcinoma were treated with Cisplatin 75mg/m2 intravenously from the first day to the third day,Gimeraciland Oteracil Porassium capsules therapy consisted of S-1 40mg/m2 given orally twice a day on days 1 to 14 of a 21-day cycle,the evaluation of efficacy and toxicity were performed on all patients after 2 cycle.Results In 35 AGC patients,CR 0,PR 18,SD 9,PD 8,effective rate is 51.4%.Conclusion Cisplatin combined with Gimeraciland Oteracil Porassium capsules in the treatment of patients with advanced gastric carcinoma has better effect with little toxicity and side effects.
出处
《中国医药指南》
2011年第19期202-203,共2页
Guide of China Medicine
关键词
替吉奥
顺铂
晚期胃癌
Gimeraciland Oteracil Porassium
Cisplatin
Patients with advanced gastric carcinoma
